Neuland Laboratories Limited (BOM:524558)
India · Delayed Price · Currency is INR 13,737
-56 (-0.41%)
At close: Jul 25, 2025
Neuland Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 14,768 | 15,586 | 11,912 | 9,511 | 9,369 | Upgrade |
Other Revenue | - | - | 2.88 | 5.99 | 0.56 | Upgrade |
| 14,768 | 15,586 | 11,915 | 9,517 | 9,370 | Upgrade | |
Revenue Growth (YoY) | -5.24% | 30.81% | 25.20% | 1.57% | 22.64% | Upgrade |
Cost of Revenue | 7,505 | 7,338 | 6,138 | 5,535 | 5,547 | Upgrade |
Gross Profit | 7,263 | 8,248 | 5,777 | 3,982 | 3,823 | Upgrade |
Selling, General & Admin | 2,734 | 2,580 | 2,026 | 1,832 | 1,505 | Upgrade |
Other Operating Expenses | 1,224 | 1,038 | 917.43 | 698.58 | 824.83 | Upgrade |
Operating Expenses | 4,613 | 4,214 | 3,471 | 3,021 | 2,726 | Upgrade |
Operating Income | 2,650 | 4,033 | 2,306 | 960.9 | 1,096 | Upgrade |
Interest Expense | -57.89 | -110.74 | -104.02 | -95.34 | -128.01 | Upgrade |
Interest & Investment Income | 105.84 | 82.27 | 15.56 | 9.95 | 16.68 | Upgrade |
Currency Exchange Gain (Loss) | 5.96 | -0.55 | -103.33 | -1.02 | -21.67 | Upgrade |
Other Non Operating Income (Expenses) | -25.08 | -29.23 | -21.45 | -34.79 | -38.19 | Upgrade |
EBT Excluding Unusual Items | 2,679 | 3,975 | 2,092 | 839.71 | 925.14 | Upgrade |
Gain (Loss) on Sale of Investments | 76.83 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -73.11 | -4.02 | -8.71 | -18.08 | 128.19 | Upgrade |
Other Unusual Items | 779.58 | 40.36 | 37.85 | - | - | Upgrade |
Pretax Income | 3,463 | 4,014 | 2,157 | 821.63 | 1,053 | Upgrade |
Income Tax Expense | 862.21 | 1,014 | 522.29 | 183.41 | 247.03 | Upgrade |
Earnings From Continuing Operations | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 | Upgrade |
Net Income | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 | Upgrade |
Net Income to Common | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 | Upgrade |
Net Income Growth | -13.32% | 83.52% | 156.21% | -20.85% | 397.40% | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | Upgrade |
EPS (Basic) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 | Upgrade |
EPS (Diluted) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 | Upgrade |
EPS Growth | -13.32% | 83.52% | 156.23% | -20.85% | 397.59% | Upgrade |
Free Cash Flow | 1,109 | 1,175 | 1,711 | -372.97 | 839.65 | Upgrade |
Free Cash Flow Per Share | 86.45 | 91.59 | 133.35 | -29.07 | 65.44 | Upgrade |
Dividend Per Share | 12.000 | 14.000 | 10.000 | 5.000 | 5.000 | Upgrade |
Dividend Growth | -14.29% | 40.00% | 100.00% | - | 150.00% | Upgrade |
Gross Margin | 49.18% | 52.92% | 48.49% | 41.84% | 40.80% | Upgrade |
Operating Margin | 17.95% | 25.88% | 19.35% | 10.10% | 11.70% | Upgrade |
Profit Margin | 17.61% | 19.25% | 13.72% | 6.71% | 8.61% | Upgrade |
Free Cash Flow Margin | 7.51% | 7.54% | 14.36% | -3.92% | 8.96% | Upgrade |
EBITDA | 3,243 | 4,588 | 2,792 | 1,404 | 1,449 | Upgrade |
EBITDA Margin | 21.96% | 29.44% | 23.43% | 14.75% | 15.47% | Upgrade |
D&A For EBITDA | 593.07 | 554.31 | 486.2 | 443.13 | 352.88 | Upgrade |
EBIT | 2,650 | 4,033 | 2,306 | 960.9 | 1,096 | Upgrade |
EBIT Margin | 17.95% | 25.88% | 19.35% | 10.10% | 11.70% | Upgrade |
Effective Tax Rate | 24.90% | 25.25% | 24.21% | 22.32% | 23.45% | Upgrade |
Revenue as Reported | 14,973 | 15,711 | 12,009 | 9,532 | 9,530 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.